Is Insulin (exogenous) or Insulin Secretagogues (Sulfonylureas) Safe with Chromium?
Free · No account · based on published sources including NIH ODS, FDA drug labels, and peer-reviewed literature
Report any episodes of dizziness, sweating, shakiness, or confusion to your diabetes care team immediately. Medication dose adjustment may be necessary.
Why this interaction occurs
Chromium III enhances insulin receptor sensitivity and potentiates insulin signaling by increasing insulin receptor tyrosine kinase activity and GLUT-4 translocation. In patients already receiving exogenous insulin or insulin secretagogues, additive glucose-lowering effects can produce clinically significant hypoglycemia. Case reports document blood glucose drops requiring emergency intervention when chromium was self-supplemented without medical supervision.
Evidence
Evidence level: moderate.
Reported safety data
The FDA’s adverse event reporting system (FAERS) has received 2,822 reports mentioning Chromium. This reflects reported cases involving the medication in general — not confirmed causation, and not specific to the Chromium + supplement combination on this page.
FAERS reports are voluntary and cannot prove that a drug caused an event. Do not use report counts to assess the safety of this specific drug-supplement pair.
Frequently asked questions
Related interactions
All Insulin (exogenous) or Insulin Secretagogues (Sulfonylureas) interactions → · All Chromium interactions →
Already checked this one — check your whole list
Educational only — not medical advice.
Always confirm with your doctor or pharmacist.